Published on 6 Oct 2024 on GuruFocus.com · via Yahoo Finance
Oncternal Therapeutics Inc (ONCT) Q2 2024 Earnings Call Highlights: Advancements...
Grant Revenue: $0.8 million for the second quarter ended June 30, 2024.Total Operating Expenses: $9.7 million for the second quarter ended June 30, 2024.Research and Development Expenses: $6.6 million for the second quarter ended June 30, 2024.General and Administrative Expenses: $3.1 million for the second quarter ended June 30, 2024.Net Loss: $8.6 million, or $2.89 per share basic and diluted, for the second quarter ended June 30, 2024.Cash, Cash Equivalents, and Short-term Investments: $21.4 million as of June 30, 2024.Shares Outstanding: Approximately 3 million shares of common stock as of June 30, 2024.